Thalys Medical Technology Inc.

Thalys Medical Technology Inc. (stoke code: 603716) was founded in February 2004. The headquarter is located in Wuhan, Hubei. We offer services for one-stop medical consumables SCM, which is characterized by “channel integration & service innovation”. The main business includes the production and sales of bundled IVD services, SPD business, regional inspection center, and IVD reagents. We are committed to establish a smart ecosystem for excellent medical products and services. Thalys has been deeply involved in the bundled medical SCM service, acquired extensive experiences in the field, and formed strong partnerships with well-known IVD suppliers in China and abroad, including SIEMENS (Germany), BE (Germany), TC (Austria), BD (US), Mindray (China), SYSMEX (Japan), Johnson & Johnson (US), Abbott Laboratories (US), Beckman (US), and BioMérieux (France). We have mapped out our future in fields of supply chain digitalization, blockchain, and IOT; have cooperated closely with Guangdong Medical Intelligent Technology Co., Ltd. (strategically invested, “120 Smart IT” and SPD IOT service platform supplier), Wuhan Kindo Medical Data Technology Co., Ltd. (strategically invested, DRGs payment system platform, national C-DRG platform supplier), Beijing Wanhu Liangfang Technology Ltd. (strategically invested, PBM chronic disease management service program) and Ant Company. We form close relationships with those who are professional in information management platform development and in big data. With their technical support, we are able to provide a better and more powerful SCM bundled services. We had had an incremental annual growth rate of 40% on sales since IPO; in 2019, the company achieved a promising operating income of ¥1,831,000,000. In the past three years, we have established 48 holding subsidiaries in more than 20 provinces nationwide with above 1200 employees, and has provided bundled SCM medical operation services for more than 300 hospital customers.